NEW YORK - NeoGenomics announced Friday it has acquired the oncology division assets of genome sequencing company Human Longevity for $37 million.
The purchase was financed via available cash on hand.
Human Longevity's oncology division performs next-generation sequencing services for pharmaceutical customers and generated about $10 million in revenue last year. NeoGenomics said the company expects the oncology division to be slightly dilutive to 2020 adjusted earnings.